Robot | Path | Permission |
GoogleBot | / | ✔ |
BingBot | / | ✔ |
BaiduSpider | / | ✔ |
YandexBot | / | ✔ |
# # robots.txt # # This file is to prevent the crawling and indexing of certain parts # of your site by web crawlers and spiders run by sites like Yahoo! # and Google. By telling these "robots" where not to go on your site, # you save bandwidth and server resources. # # This file will be ignored unless it is at the root of your host: # Used: http://example.com/robots.txt # Ignored: http://example.com/site/robots.txt # # For more information about the robots.txt standard, see: # http://www.robotstxt.org/robotstxt.html User-agent: * Crawl-delay: 10 # CSS, JS, Images Allow: /misc/*.css$ Allow: /misc/*.css? Allow: /misc/*.js$ Allow: /misc/*.js? Allow: /misc/*.gif Allow: /misc/*.jpg Allow: /misc/*.jpeg Allow: /misc/*.png Allow: /modules/*.css$ Allow: /modules/*.css? Allow: /modules/*.js$ Allow: /modules/*.js? Allow: /modules/*.gif Allow: /modules/*.jpg Allow: /modules/*.jpeg Allow: /modules/*.png Allow: /profiles/*.css$ Allow: /profiles/*.css? Allow: /profiles/*.js$ Allow: /profiles/*.js? |
Title | amaltherapeutics.com - Transforming the prospects of cancer |
Description | Harnessing the power of KISIMA® immunisation technology to discover and develop therapeutic Harnessing the power of KISIMA® immunisation technology to discover and develop therapeutic |
Keywords | N/A |
WebSite | amaltherapeutics.com |
Host IP | 45.60.72.30 |
Location | United States |
Site | Rank |
US$3,397,520
Last updated: 2023-05-07 16:55:39
amaltherapeutics.com has Semrush global rank of 3,115,303. amaltherapeutics.com has an estimated worth of US$ 3,397,520, based on its estimated Ads revenue. amaltherapeutics.com receives approximately 392,022 unique visitors each day. Its web server is located in United States, with IP address 45.60.72.30. According to SiteAdvisor, amaltherapeutics.com is safe to visit. |
Purchase/Sale Value | US$3,397,520 |
Daily Ads Revenue | US$3,137 |
Monthly Ads Revenue | US$94,086 |
Yearly Ads Revenue | US$1,129,022 |
Daily Unique Visitors | 26,135 |
Note: All traffic and earnings values are estimates. |
Host | Type | TTL | Data |
amaltherapeutics.com. | A | 7199 | IP: 45.60.72.30 |
amaltherapeutics.com. | A | 7199 | IP: 45.60.65.30 |
amaltherapeutics.com. | NS | 43200 | NS Record: ns3.nameshield.net. |
amaltherapeutics.com. | NS | 43200 | NS Record: ns2.observatoiredesmarques.fr. |
amaltherapeutics.com. | NS | 43200 | NS Record: obs.ns1.fr. |
amaltherapeutics.com. | MX | 43200 | MX Record: 10 mail3.boehringer-ingelheim.com. |
amaltherapeutics.com. | MX | 43200 | MX Record: 10 mail2.boehringer-ingelheim.com. |
amaltherapeutics.com. | MX | 43200 | MX Record: 10 mail1.boehringer-ingelheim.com. |
amaltherapeutics.com. | MX | 43200 | MX Record: 10 mail4.boehringer-ingelheim.com. |
amaltherapeutics.com. | TXT | 43200 | TXT Record: v=spf1 include:_spf.google.com ~all |
amaltherapeutics.com. | TXT | 43200 | TXT Record: d4d5jjvwym0nkz7q4k6ch8fjb92qjsf0 |
amaltherapeutics.com. | TXT | 43200 | TXT Record: globalsign-domain-verification=32DF1F5761E5AC75D1ADAABBC97CAFAB |
amaltherapeutics.com. | TXT | 43200 | TXT Record: facebook-domain-verification=lk2g4jd9zybzczccflxjcx6isr6i2h |
amaltherapeutics.com. | TXT | 43200 | TXT Record: MS=ms39392557 |
amaltherapeutics.com. | TXT | 43200 | TXT Record: google-site-verification=XB5lrYrmnfSHPGvJqOzYCsPAf_MISfHy-hvP2hZRPco |
--> --> --> About us Overview Management Team Board of Directors Scientific Advisory Board Clinical Advisory Board Science Therapeutic Vaccines KISIMA ® Publications Pipeline Partnering Partnering at AMAL Therapeutics Partnering at Boehringer Ingelheim Media News Events Careers Contact --> --> Harnessing the power of KISIMA ® immunisation technology to discover and develop therapeutic vaccines A novel approach to therapeutic vaccines AMAL aims to tackle the obstacles for effective anti-cancer therapy by stimulating a patient’s immune system in a unique way. More about AMAL First-in-class immunisation technology KISIMA ® , our unique proprietary protein-based immunisation platform is self-adjuvanting and delivers several antigens in one single vaccine. More about KISIMA ® Transforming the prospects of cancer patients We focus on the development of viable effective cancer therapies. Our most advanced asset is ATP128, a therapeutic vaccine for the treatment of metastatic |
HTTP/1.1 301 Moved Permanently Location: https://amaltherapeutics.com/ Content-Length: 0 Connection: close HTTP/2 308 location: https://www.amaltherapeutics.com/ content-length: 0 strict-transport-security: max-age=31536000 HTTP/2 403 content-type: text/html cache-control: no-cache, no-store content-length: 860 x-iinfo: 12-70613824-0 0NNN RT(1635415472994 0) q(0 -1 -1 0) r(0 -1) B15(4,200,0) U5 strict-transport-security: max-age=31536000 set-cookie: visid_incap_2524565=+rXYOvRvQi+cryH06sfHdbB1emEAAAAAQUIPAAAAAAB3dtcbOmLroR28wgZD59gd; expires=Fri, 28 Oct 2022 08:26:30 GMT; HttpOnly; path=/; Domain=.amaltherapeutics.com; Secure; SameSite=None set-cookie: incap_ses_113_2524565=hwVRBufwZRsljvItW3WRAbB1emEAAAAAITYGPZb0Cl1ygHTtEdS/RQ==; path=/; Domain=.amaltherapeutics.com; Secure; SameSite=None |
Domain Name: AMALTHERAPEUTICS.COM Registry Domain ID: 1742376982_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.nameshield.net Registrar URL: http://www.nameshield.net Updated Date: 2021-09-01T22:02:21Z Creation Date: 2012-09-03T14:48:48Z Registry Expiry Date: 2023-09-03T14:48:48Z Registrar: NAMESHIELD SAS Registrar IANA ID: 1251 Registrar Abuse Contact Email: abuse@nameshield.net Registrar Abuse Contact Phone: +33241182828 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: NS2.OBSERVATOIREDESMARQUES.FR Name Server: NS3.NAMESHIELD.NET Name Server: OBS.NS1.FR DNSSEC: unsigned >>> Last update of whois database: 2021-09-16T02:58:00Z <<< |